US · Basic Materials · Specialty Chemicals
EPS came in at -0.64 against a street estimate of -0.57 — a miss of 12.3%.
Analysts rate Calumet Specialty Products Partners a buy (4 buy, 3 hold, 0 sell out of 7) with an average price target of $39.60.
| Fund | Stake |
|---|---|
| Two Seas Capital LP | 6.84% |
| BlackRock Inc | 5.72% |
| Wasserstein Debt Opportunities Management LP | 5.25% |
| Vanguard Capital Management, LLC | 3.94% |
| State Street Corp | 3.53% |
| Adams Asset Advisors LLC | 2.30% |
| Geode Capital Management, LLC | 2.15% |
| Bank of America Corp | 1.32% |
| Document | Date |
|---|---|
| Shareholder vote results · Q2 2026 | 2026-06-03 |
| Quarterly report · Q1 2026 | 2026-05-08 |
| Results announced · Q2 2026 | 2026-05-08 |
| Proxy statement · Q2 2026 | 2026-04-20 |
| Board / officer change · Q1 2026 | 2026-03-25 |
| Material agreement · Q1 2026 | 2026-03-17 |
| Annual report FY2025 | 2026-02-27 |
| Quarterly report · Q3 2025 | 2025-11-10 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Calumet Specialty Products Partners — free to start.
Google PlayApp StoreData updated 2026-08-05.